➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Mallinckrodt
Medtronic
McKinsey
Baxter

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

Anidulafungin - Generic Drug Details

» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for anidulafungin and what is the scope of patent protection?

Anidulafungin is the generic ingredient in one branded drug marketed by Vicuron and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Anidulafungin has sixty-seven patent family members in twenty-nine countries.

There are two drug master file entries for anidulafungin. One supplier is listed for this compound.

Summary for anidulafungin
International Patents:67
US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: 2
Suppliers / Packagers: 1
Bulk Api Vendors: 35
Clinical Trials: 34
Patent Applications: 2,406
DailyMed Link:anidulafungin at DailyMed
Recent Clinical Trials for anidulafungin

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Radboud UniversityPhase 4
Universidade Federal do Rio de JaneiroPhase 4
Fundacion SEIMC-GESIDAPhase 4

See all anidulafungin clinical trials

Pharmacology for anidulafungin

US Patents and Regulatory Information for anidulafungin

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for anidulafungin

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006   Start Trial   Start Trial
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006   Start Trial   Start Trial
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006   Start Trial   Start Trial
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006   Start Trial   Start Trial
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006   Start Trial   Start Trial
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for anidulafungin

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0561639 SPC002/2008 Ireland   Start Trial SPC002/2008: 20081105, EXPIRES: 20180317
0561639 C00561639/01 Switzerland   Start Trial PRODUCT NAME: ANIDULAFUNGIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 58325 03.09.2009
0561639 08C0009 France   Start Trial PRODUCT NAME: ANIDULAFUNGINE; REGISTRATION NO/DATE: EU/1/07/416/001 20070920
0561639 CA 2008 00017 Denmark   Start Trial
0561639 C300334 Netherlands   Start Trial PRODUCT NAME: ANIDULAFUNGIN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/07/416/001 20070920
0561639 300334 Netherlands   Start Trial 300334, 20130318, EXPIRES: 20180317
0561639 91406 Luxembourg   Start Trial 91406, EXPIRES: 20180318
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Mallinckrodt
Medtronic
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.